2 research outputs found
Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5?6 years after completion of the primary series
10.1080/21645515.2019.1661204Human Vaccines & Immunotherapeutics163523-52
Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, Phase II trials
10.1080/21645515.2019.1578595Human Vaccines & Immunotherapeutics15102315-232